Affiliation:
1. Division of Enteric Diseases, Naval Medical Research Institute, Bethesda, Maryland 20889-5607.
Abstract
The effect of oral recombinant interleukin (rIL) treatment on the course of Campylobacter jejuni infection and the development of mucosal immunity in mice was investigated. rIL-2, rIL-5, and rIL-6 were administered to mice at 24 and 6 h before infection and at 0, 24, and 48 h after infection with C. jejuni HC, and the subsequent development of an immune response and intestinal colonization resistance were determined. In this model, orally administered cytokines retained their biological activities with no apparent side effects. Following infection, initial bacterial counts in fecal samples collected from cytokine-treated and untreated mice were similar. However, within 48 h of infection a greater than 3-log-unit reduction in the number of C. jejuni shed in the feces was found for rIL-6-treated animals. Colonization levels were similarly reduced in rIL-5-treated mice, although the rate of clearance was somewhat slower. In contrast, rIL-2 treatment had no significant effect on colonization levels compared with that in controls. Oral rIL-6 treatment was also associated with enhanced intestinal and systemic Campylobacter-specific immunoglobulin A responses compared with those observed in either rIL-5- or rIL-2-treated animals. Upon rechallenge, initial colonization in all cytokine-treated groups was approximately 2 log units lower than that in controls. However, local infection was controlled only in rIL-2-treated mice over time. rIL-5 and rIL-6 treatment had only a marginal effect on colonization resistance following rechallenge. On the basis of these results, it appears that rIL-5 or rIL-6 may function to modulate the induction and/or expression of anti-C. jejuni immunity through different mechanisms.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference33 articles.
1. Baqar S. and A. L. Bourgeois. 1993. Unpublished data.
2. Natural killer cell activity and macrophage-dependent inhibition of growth or killing of Mycobacterium avium complex in mouse model;Bermudez L. E.;J. Leukocyte Biol.,1990
3. Treatment of experimental disseminated Mycobactenium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor;Bermudez L. E.;J. Immunol.,1989
4. Experimental Campylobacter jejuni infection in humans;Black R. E.;J. Infect. Dis.,1988
5. Cytokine activation of killer cells in mycobacterial immunity;Blanchard D. K.;Adv. Exp. Med. Biol.,1992
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献